InVivo Biosystems Raises $3M for CRISPR Research and Welcomes New Board Chairman
InVivo Biosystems, operating in the realm of CRISPR-edited animal models for biomedical research, has recently embarked on a new phase …
All Posts
Bioptimus: Pioneering LLMs in Biotechnology
Executives from the French AI drug discovery company Owkin have embarked on a new venture, launching Bioptimus, a startup dedicated …
AI Breaches the Barrier Towards Better CNS Drug Discovery
The sphere of oncology continues to grapple with the complex nature of brain and central nervous system (CNS) tumors. Data …
Bristol Myers Squibb Acquires RayzeBio in a Strategic Move to Expand Radiopharmaceutical Capabilities
In a significant development in the pharmaceutical industry, Bristol Myers Squibb (BMS) has announced the acquisition of RayzeBio, a company …
Biopharma Industry Review: A Year of Challenges and Changes in 2023
The biopharma industry experienced a challenging year in 2023, marked by a significant decrease in funding and a high number …
The Rising Popularity of Antibody-Drug Conjugates, with Challenges
In the current climate of global economic uncertainty, one area of pharmaceutical development is bucking the trend with a significant …
C4 Therapeutics and Merck Collaborate on Innovative Cancer Treatment
In a recent move in the biotechnology sector, C4 Therapeutics, Inc. (C4T) has announced a collaboration with pharmaceutical giant Merck …
LegoChem Biosciences Strikes Licensing Deal with Janssen for ADC Development
In a new development in the field of cancer treatment, LegoChem Biosciences, Inc., a South Korean biopharmaceutical firm, has announced …
Addressing Inequity in Medical Research: The Need to Expand Genomic Databases
Precision medicine is fast developing, with genomics being a particularly promising field. As genomic medicine advances, we get steadily closer …
Unnatural Products Secures $32M to Advance Drug Development with AI-Enhanced Macrocycles
Santa Cruz-based biotech company, Unnatural Products, Inc. (UNP), has recently secured a significant investment of $32 million in its Series …
SiSaf Advances in Alopecia Treatment with Phase II Trial of Bio-Courier® Technology
In a new development in the field of dermatological therapeutics, SiSaf Ltd, a biopharmaceutical company based in Guildford, UK, has …
Vandria Gains Momentum with $20.6M Funding to Propel Novel CNS and Mitochondrial Therapies
Vandria SA, a Swiss biotechnology firm specializing in mitochondrial therapeutics, recently announced a significant milestone in its journey. The company …